Leerink Partners analyst Daina Graybosch has maintained their bullish stance on BNTX stock, giving a Buy rating yesterday.
Daina Graybosch’s rating is based on the strategic importance of BioNTech’s COVID-19 vaccine dynamics in the near term, despite potential regulatory challenges in the U.S. that could impact vaccine sales. The company’s COVID-19 vaccine sales are crucial for funding its ambitious oncology plans, and BioNTech has reported stable interactions with the FDA regarding its vaccine.
Additionally, BioNTech’s development strategy for its bispecific program, BNT327, is expected to stand out in the mid-term. The company’s approach involves combining BNT327 with traditional chemotherapy and antibody drug conjugates, with early safety data showing no additional toxicity. This differentiated strategy, along with a strong financial position, supports the Buy rating.
According to TipRanks, Graybosch is an analyst with an average return of -15.5% and a 32.02% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as BioNTech SE, Gilead Sciences, and Merck & Company.
In another report released yesterday, Berenberg Bank also maintained a Buy rating on the stock with a $130.00 price target.